Overview

This trial is active, not recruiting.

Condition non-small cell lung cancer
Treatments ipilimumab, erlotinib, crizotinib, nivolumab
Phase phase 1
Targets PD-1, c-MET, ALK, EGFR, CTLA-4, ROS1
Sponsor University of Utah
Collaborator Bristol-Myers Squibb
Start date December 2013
End date December 2017
Trial size 14 participants
Trial identifier NCT01998126, HCI66705

Summary

The goals of the overall study are to evaluate a recommended phase 2 dose and the short and long term toxicities of the combinations. This is a modified phase I trial of immune checkpoint inhibitors in combination with mutation - specific targeted therapy (crizotinib or erlotinib) at conventional doses stratified for presence of ALK (Anaplastic lymphoma kinase) or EGFR (epidermal growth factor receptor) mutation.

The goals of the overall study are to evaluate a recommended phase 2 dose and the short and long term toxicities of the combinations.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
ipilimumab and erlotinib in EGFR mutated patients
ipilimumab Yervoy
Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)
erlotinib
Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)
(Experimental)
ipilimumab and crizotinib in ALK mutated patients
ipilimumab Yervoy
Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)
crizotinib
Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)
(Experimental)
nivolumab and erlotinib in EGFR mutated patients
erlotinib
Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)
nivolumab Nivolumab 240 mg every 2 weeks
(Experimental)
nivolumab and crizotinib in ALK mutated patients
crizotinib
Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)
nivolumab Nivolumab 240 mg every 2 weeks

Primary Outcomes

Measure
toxicity of ipilimumab and erlotinib in EGFR mutated patients
time frame: 36 months
toxicity of ipilimumab and crizotinib in ALK mutated patients
time frame: 36 months
toxicity of nivolumab and erlotinib in EGFR mutated patients
time frame: 36 months
toxicity of nivolumab and crizotinib in ALK mutated patients
time frame: 36 months

Secondary Outcomes

Measure
Response rate
time frame: 36 months
Progression Free Survival (PFS)
time frame: 36 months
Overall Survival
time frame: 36 months
immune function pre and post immune therapy
time frame: 36 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Diagnosis of Stage IV Non-Small Cell Lung Cancer (NSCLC), or Stages II - III NSCLC that cannot be treated curatively with standard techniques. - Non-Small Cell Lung Cancer (NSCLC) that is either EGFR or ALK mutated. - Untreated with/or actively treated with specific inhibitor for less than 6 months if not progressing on active therapy. - Age > 18. - ECOG performance status 0, 1 or 2. - Prior chemotherapy is allowed if > one month from the end of treatment. Patients must not have received chemotherapy within 4 weeks of the start of study drug. - Brain metastases are allowed if the patient is asymptomatic or previous steroid treatment was discontinued > 6 weeks. - Adequate bone marrow function as defined in the protocol - Serum bilirubin levels < 1.5 mg/dL except for patients with Gilbert's syndrome. - Adequate organ function as defined in the protocol - If female and of childbearing potential, documentation of negative pregnancy test (serum or urine) within 7 days prior to first dose. - Able to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines. Exclusion Criteria: - Concurrent therapy with any other non-protocol anti-cancer therapy. - History of any other malignancy requiring active treatment. - Patients who have had a history of acute diverticulitis, intra-abdominal abscess, Gastrointestical obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation. - History of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome). History of vitiligo and adequately controlled endocrine deficiencies such as hypothyroidism are allowed. - Significant cardiovascular disease including: - Active, clinically symptomatic left ventricular failure. - Uncontrolled symptomatic hypertension that cannot be controlled with anti-hypertensive agents. - Myocardial infarction, severe angina, or unstable angina within 6 months prior to administration of first dose of study drug. - History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) - Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication) - Coronary or peripheral artery bypass graft within 6 months of screening. - Uncontrolled CNS metastases are not allowed; subjects with previously treated brain metastases will be allowed if the brain metastases have been treated, toxicities have resolved to grade 1 or baseline and steroids are no longer required. Leptomeningeal metastases are not allowed. - Serious/active infection or infection requiring parenteral antibiotics. - Pregnant or lactating females. - HIV infection or chronic hepatitis B or C. Negative Screening tests for HIV, Hepatitis B, and Hepatitis C are required. - The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complications.

Additional Information

Official title Evaluation of Combination Checkpoint Inhibitor Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by University of Utah.
Location data was received from the National Cancer Institute and was last updated in August 2016.